Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRA in Patients With pJIA
NCT00144664Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2004
- Primary completion
- Apr 2005
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in polyarticular juvenile idiopathic arthritis and Oligoarticular Juvenile Idiopathic Arthritis (oJIA), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: JIA Core Set 30% Improvement, Incidence and severity of adverse events and adverse drug reactions and 1 more. Started Nov 2004; status: completed.
02
Drugs
tocilizumab
03
Conditions
polyarticular juvenile idiopathic arthritisOligoarticular Juvenile Idiopathic Arthritis (oJIA)
Beyond the preview
Go deeper on NCT00144664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144664.